Related Experiment Videos
A myeloperoxidase promoter polymorphism is independently associated with mortality in patients with impaired left
Volker Rudolph1, Tanja K Rudolph, Lukas Kubala
1Department of Cardiology, University Heart Center Hamburg, 20246 Hamburg, Germany. v.rudolph@uke.de
Abstract:
Circulating levels of myeloperoxidase (MPO), a heme enzyme released upon activation of polymorphonuclear neutrophils, predict adverse outcome in patients with impaired left ventricular (LV) function. The MPO -463 G/A promoter polymorphism (rs 2333227) regulates MPO transcription, with the G allele being linked to increased protein expression. The aim of this study was to assess the prognostic information derived from the -463 G/A MPO polymorphism on outcomes of patients with impaired LV function. The -463 G/A promoter MPO genotype as well as MPO plasma levels were determined in 116 patients with impaired LV function. Patients were prospectively followed for a median of 1050 days. The GG genotype was associated with a decrease in overall survival (chi(2) 5.80; p=0.016). This association remained after multivariate adjustment for plasma levels of NT-proBNP, creatinine, hsCRP, and MPO; leukocyte count; and LV function (hazard ratio 3.16 (95% CI 1.17-8.53), p=0.024) and for classical cardiovascular risk factors (hazard ratio 2.88 (95% CI 1.13-7.33), p=0.026). Interestingly, we observed no association of the MPO polymorphism with total MPO protein concentration or MPO activity in plasma. The -463 G/A MPO polymorphism is linked to adverse clinical outcome of patients with impaired LV function. Further studies are needed to elucidate the value of this polymorphism for risk stratification.
Insights
The myeloperoxidase (MPO) -463 G/A polymorphism, specifically the GG genotype, is linked to poorer survival in patients with impaired left ventricular (LV) function. This genetic marker offers prognostic information independent of MPO levels.
Area of Science:
- Cardiovascular Genetics
- Molecular Cardiology
- Biomarkers
Background:
- Circulating myeloperoxidase (MPO) levels predict adverse outcomes in patients with impaired left ventricular (LV) function.
- The MPO -463 G/A promoter polymorphism influences MPO transcription, with the G allele associated with higher protein expression.
Purpose of the Study:
- To investigate the prognostic value of the MPO -463 G/A polymorphism in patients with impaired LV function.
- To determine if this genetic variant provides independent prognostic information beyond established clinical factors.
Main Methods:
- Genotyping for the MPO -463 G/A polymorphism and measurement of plasma MPO levels in 116 patients with impaired LV function.
- Prospective follow-up for a median of 1050 days to assess overall survival.
- Multivariate analysis adjusting for clinical variables, cardiovascular risk factors, and biomarkers like NT-proBNP and hsCRP.
Main Results:
- The GG genotype of the MPO -463 G/A polymorphism was significantly associated with decreased overall survival (p=0.016).
- This association remained significant after multivariate adjustment for clinical factors and biomarkers (HR 3.16, p=0.024).
- No correlation was found between the MPO polymorphism and plasma MPO protein concentration or activity.
Conclusions:
- The MPO -463 G/A polymorphism is an independent predictor of adverse clinical outcomes in patients with impaired LV function.
- This genetic marker may contribute to risk stratification in this patient population.
- Further research is warranted to fully elucidate the clinical utility of this polymorphism.
Related Concept Videos
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu